Rex Fang & Innovation Equity Premium Income ETF vs Medtronic PLC — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.36, while Medtronic PLC trades at $83.54 (market cap $103.01B). The key difference: Medtronic PLC pays a 3.58% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none. Which is the better fit depends on your goals.
| FEPI | MDT | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $105.35 |
52-Week Low | $38.13 | $73.75 |
Market Cap | — | $103.01B |
Enterprise Value | — | $121.75B |
Dividend Yield | — | 3.58% |
Signals from Pluang's Aura AI — not financial advice
FEPI trades at $41.40, down 2.45% over the past day, with technical indicators signaling a bearish trend. The ETF generates a high yield through weekly covered call distributions, but its concentrated tech holdings and call-writing strategy cap upside potential while exposing investors to net asset value erosion during market downturns. Recent news highlights its 25% yield appeal but cautions on structural limitations.
Outlook remains cautious due to the ETF's high-risk income strategy; opportunities exist for yield-seeking investors comfortable with capped gains and volatility, but risks include underperformance versus benchmarks and NAV decay in declining markets. Investor sentiment is mixed, balancing high income against long-term growth constraints.
Medtronic (MDT) trades at $83.19, up 4.91% over the past 24 hours, with a technical outlook that is bearish based on moving averages but supported by neutral oscillators. The stock has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $1.55 surpassing the $1.54 estimate. Revenue grew to $33.54 billion in 2025, and the company maintains strong profitability with a net income margin of 13.2%. Recent corporate actions include a $0.72 dividend payment scheduled for July 2026.
The outlook for MDT is positive, supported by robust fundamentals, a favorable analyst consensus with a $97.50 price target, and a dividend aristocrat status. Key risks include increasing debt levels and competitive pressures in the medical device sector. The stock presents a long-term opportunity for growth and income, though near-term technical weakness may persist.
Trailing returns across standard periods
Latest headlines on both assets
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →